Benzinga
Benzinga
Benzinga
lunes, septiembre 28

Tempest Therapeutics Inc

TPSTNASDAQ
Trade with Public
Trade with Public
$0.8128
-0.0162-1.95%
Últ. Act.: Sep 28, 10:19 AM
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararInforme de acciones

Tempest Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Tempest Therapeutics (TPST).

Price Target Range — 9 Quarters

Analyst Consensus — 4 Analysts

3Buy
1Hold
Consensus RatingBuy# Analysts4Avg. Consensus PT$27Upside to Avg. PT+3221.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →
DateFirmAnalystActionRating ChangePrice Target
Sep 24, 2026HC Wainwright & Co.Joseph PantginisPT CutBuy$11→$7
Jan 22, 2026HC Wainwright & Co.Joseph PantginisUpgradeNeutral→Buy$11
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on Tempest Therapeutics, Lowers Price Target to $7

HC Wainwright & Co. analyst Joseph Pantginis maintains Tempest Therapeutics (NASDAQ:TPST) with a Buy and lowers the price target from $11 to $7.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Upgrades Tempest Therapeutics to Buy, Announces $11 Price Target

HC Wainwright & Co. analyst Joseph Pantginis upgrades Tempest Therapeutics (NASDAQ:TPST) from Neutral to Buy and announces $11 price target.
Benzinga Newsdesk

Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success

Tempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited interest in its liver cancer program.
Vandana Singh

PRO
Correction : Scotiabank Downgrades Tempest Therapeutics to Sector Perform, Raises Price Target to $9 (Previous Target changed)

Correction: Scotiabank analyst George Farmer downgrades Tempest Therapeutics (NASDAQ:TPST) from Sector Outperform to Sector Perform and raises the price target from $7 to $9. (Previous Target changed)
Benzinga Newsdesk

PRO
HC Wainwright & Co. Downgrades Tempest Therapeutics to Neutral, Maintains Price Target to $16

HC Wainwright & Co. analyst Joseph Pantginis downgrades Tempest Therapeutics (NASDAQ:TPST) from Buy to Neutral and maintains the price target from $16 to $16.
Benzinga Newsdesk

PRO
Scotiabank Maintains Sector Outperform on Tempest Therapeutics, Lowers Price Target to $7

Scotiabank analyst George Farmer maintains Tempest Therapeutics (NASDAQ:TPST) with a Sector Outperform and lowers the price target from $13 to $7.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved